Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors

Modern Pathology

Volumn 25, Issue 9, 2012, Pages 1258-1264

  Walts, Ann E ^a   Ines, Delma ^a   Marchevsky, Alberto M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

atypical carcinoid; carcinoid; Ki 67; pulmonary

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL PULMONARY CARCINOID TUMOR; BRONCHUS CARCINOID; CANCER CLASSIFICATION; CANCER STAGING; CARCINOID; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; INDEPENDENT VARIABLE; LUNG TUMOR; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TYPICAL PULMONARY CARCINOID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CARCINOID TUMOR; CELL PROLIFERATION; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865799007     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.81     Document Type: Article

References (38)

1. Chen LC, Travis WD, Krug LM. Pulmonary neuroendocrine tumors: what (little) do we know? J Natl Compr Canc Netw 2006;4:623-630.
2. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21(Suppl 7):vii65-vii71.
3. Travis WD, Giroux DJ, Chansky K, et al. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TMN classification for lung cancer. J Thorac Oncol 2008;3:12131223.
4. American Joint Committee on Cancer. Neuroendocrine tumors, chapter 17. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A (eds). AJCC Cancer Staging Manual 7th edn Springer: New York, 2010, pp 181-185.
5. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumors. Eur Respir J 2001;18:1059-1068.
6. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255-1265.
7. Mezzetti M, Raveglia F, Panigalli T, et al. Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg 2003;76:1838-1842.
8. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-944.
9. Santinelli A, Ranaldi R, Baccarini M, et al. Ploidy, proliferative activity, p53, and bcl-2 expression in bronchopulmonary carcinoids: relationship with prognosis. Pathol Res Pract 1999;195:467-474.
10. Warth A, Herpel E, Krysa S, et al. Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Exp Mol Med 2009;41:349-353.
11. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798-810.
12. Zirbes TK, Lorenzen J, Baldus SE, et al. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumor cell turnover in primary carcinoid tumors of the lung. Histopathology 1998;33:123-128.
13. Raatz H, Bocking A, Hauptmann S. Prognostic impact of DNA-image-cytometry in neuroendocrine (carcinoid) tumors. Cell Oncol 2004;26:81-88.
14. Pelosi G, Pasini F, Fraggetta F, et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003;42:203-213.
15. Skov BG, Holm B, Erreboe A, et al. ERCC1 and Ki-67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 2010;5:453-459.
16. Laitinen KLJ, Soini Y, Mattila J, et al. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and prolfierative activity. Cancer 2000;88:1590-1598.
17. Lin O, Olgac S, Green I, et al. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003;120:209-216.
18. Igarashi T, Jiang SX, Kameya T, et al. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004;17:1259-1267.
19. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosisrelated factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-1952.
20. Di Stefano P, Natoli C, Iacobelli S, et al. DNA ploidy and S-phase fraction in pulmonary carcinoids. Eur J Cancer 1992;28A:1933-1934.
21. Gal R, Rath-Wolfson L, Rosenblatt Y, et al. An improved technique for mitosis counting. Int J Surg Pathol 2005;13:161-165.
22. Facchetti F. A proposal for the adoption of a uniform metrical system for mitosis countig. Int J Surg Pathol 2005;13:157-159.
23. Rosai J. Mitotic count in tumors. Int J Surg Pathol 2005;13:155.
24. Tungekar MF, Gatter KC, Dunnill MS, et al. Ki-67 immunostaining and survival in operable lung cancer. Histopathology 1991;19:545-550.
25. Costes V, Marty-Ane C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67 labeling study. Hum Pathol 1995;26:740745.
26. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-2025.
27. Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: Phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008;14:149-154.
28. Bohm J, Koch S, Gais P, et al. Prognostic value of MIB-1 in neuroendocrine tumors of the lung. J Pathol 1996;178:402-409.
29. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-712.
30. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors : a consensus proposal including a grading system. Virchows Arch 2006;449:395401.
31. Colby TV, Koss MN, Travis WD. Carcinoid and other neuroendocrine tumors In: Rosai J, Sobin LH (eds). Atlas of Tumor Pathology. Tumors of the Lower Respiratory Tract. Third series. Fascicle 13. AFIP: Washington, DC, 1995, pp 287-309.
32. www.cancer.org.
33. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006;130:1026-1030.
34. Zimmermann ME, Bosman FT. Proliferative activity of well differentiated neuroendocrine tumors of the gut. Histol Histopathol 2003;18:353-358.
35. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki-67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011;35:853-860.
36. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology dataset. Am J Surg Pathol 2010;34:300-313.
37. Granberg D, Wilander E, Oberg K, et al. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000;85:3425-3430.
38. Al-Khafaji B, Noffsinger AE, Miller MA, et al. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors. Hum Pathol 1998;29:992-999.